HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis.

Abstract
Rheumatoid arthritis (RA) is a crippling autoimmune disease which afflicts over 1% of the population. Non-steroidal anti-inflammatory drugs are widely used palliatives, but these disease-modifying drugs are of variable and limited efficacy, and are frequently associated with side-effects which restrict their use. Agents that elevate cAMP, including cAMP-specific phosphodiesterase (PDE) inhibitors, possess a profile of anti-inflammatory activities which suggest potential benefit in RA. In several rodent RA models, PDE IV inhibitors reduce the incidence and severity of disease symptoms and histological analysis reveals a significant, beneficial effect on joint pathology. Several potential mechanisms may underpin the anti-arthritic actions of PDE IV inhibitors. These include inhibition of tumor necrosis factor (TNF)-alpha release, increase of interleukin (IL)-10 release, and suppression of T-lymphocyte function, as well as direct, protective effects on cartilage and bone. Although stimulation of the hypothalamic-pituitary-adrenal axis in rodents has previously been suggested as a possible mechanism by which PDE IV inhibitors exert their anti-arthritic effects, recent data question its importance. For example, RP-73401 ameliorates disease severity in Streptococcal cell wall-induced arthritis in Lewis rats, a strain whose susceptibility to this disease has been attributed to a defective HPA response, without affecting either ACTH or corticosterone levels. In a small clinical study, RA patients treated with low doses of RP-73401, showed a positive (non-significant) trend in respect of serum concentrations of IL-6 and CRP. Although levels of TNFalpha and IL-1beta were unaffected, patients reported some symptomatic relief. The administration of higher doses was prohibited due to side-effects and compounds with an improved therapeutic window will have to be identified to further explore the potential of PDE IV inhibitors in the treatment of RA.
AuthorsJ E Souness, M Foster
JournalIDrugs : the investigational drugs journal (IDrugs) Vol. 1 Issue 5 Pg. 541-53 (Sep 1998) ISSN: 1369-7056 [Print] England
PMID18465594 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: